Anti-IL17A Monoclonal antibody, APC

We investigated the effects of IL-17A rs2275913 and IL-17F rs763780 polymorphisms on IL-17 expression and the association of these polymorphisms with the risk of gastritis and gastric cancer. IL-17A expression was closely associated with the degree of gastritis in 55 non-neoplastic gastric mucosae and was markedly decreased in subjects carrying A allele. In addition, IL-17F expression was increased in the T allele carriers, but was not associated with gastritis. In 300 gastric cancer patients, the frequency of the rs2275913 A/A genotype was significantly higher in intestinal-type gastric cancer, when compared to that of diffuse-type gastric cancer (P>0.05). There was a significant difference in genotype distribution and allele frequencies of IL-17F rs763780 when comparing gastric cancer patients and 247 healthy controls. These results suggest that the polymorphisms of IL-17F rs763780 and IL-17A rs2275913 are closely associated with susceptibility to the development of gastritis and gastric cancer in the Korean population.

Objective To evaluate the predictive value of genetic polymorphisms in the context of bacille Calmette-Guerin (BCG) immunotherapy outcome and create a predictive profile that may allow discrimination of the risk of recurrence. Patients and Methods In a dataset of 204 patients treated with BCG, we evaluated 42 genetic polymorphisms in 38 genes involved in the BCG mechanism of action, using Sequenom MassARRAY (R) technology. Stepwise multivariate Cox regression was used for data mining. Results In agreement with previous studies we found that gender, age, tumour multiplicity and treatment scheme were associated with BCG failure. Using stepwise multivariate Cox regression analysis we propose the first predictive profile of BCG immunotherapy outcome and a risk score based on polymorphisms in immune system molecules [single nucleotide polymorphisms in tumour necrosis factor a (TNFA)-1031T/C (rs1799964), interleukin 2 receptor a (IL2RA) rs2104286 T/C, IL17A-197G/A (rs2275913), IL17RA-809A/G (rs4819554), IL18R1 rs3771171 T/C, intercellular adhesion molecule 1 (ICAM-1) K469E (rs5498), Fas ligand (FASL)-844T/C (rs763110) and TNF-related apoptosis-inducing ligand receptor 1 (TRAILR1)-397T/G (rs79037040)] in association with clinicopathological variables. This risk score allows the categorisation of patients into risk groups: patients within the low-risk group have a 90% chance of successful treatment, whereas patients in the high-risk group present a 75% chance of recurrence after BCG treatment. Conclusion We have established the first predictive score of BCG immunotherapy outcome combining clinicopathological characteristics and a panel of genetic polymorphisms. Further studies using an independent cohort are warranted. Moreover, the inclusion of other biomarkers may help to improve the proposed model.